Tg Therapeutics, Inc.

This study tests a drug called ublituximab for people with relapsing multiple sclerosis. It compares injecting the drug under the skin at different body sites and using an auto-injector device versus a regular syringe. The goal is to see how the drug moves through the body and if…

This study tests a drug called ublituximab in children aged 10 to under 18 with relapsing multiple sclerosis (MS). The goal is to see if it works better than another MS drug, fingolimod, at reducing flare-ups. About 240 participants will receive the drug and be monitored for safe…

This study tracks 32 people with B-cell autoimmune disorders who previously received Azer-Cel, an experimental cell therapy. Researchers will monitor for side effects and disease changes for up to 15 years. The goal is to understand the long-term safety of this treatment.